1988 INSERM Researcher 2nd class at INSERM U36 (P Corvol)
1992 INSERM Researcher 1st class at INSERM U36 (P Corvol)
1997 INSERM Research Director 2nd class at INSERM U36 (P Corvol)
2000 INSERM Research Director 2nd class at INSERM U744 (P Amouyel)
Research laboratory : INSERM U744- IPL- 1 rue du professeur Calmette-59019 Lille cedex . Directeur : Pr P.AMOUYEL
1983 MASTER in Molecular and Cellular Pharmacology (Paris VI)
Role of glucocorticoides on angiotensinogen production by primary cultures of cultures hepatocytes (INSERM U36)
1987 PhD in Molecular and Cellular Pharmacology (Paris VI)
1984 Zurich University (Switzerland, Professor M. Celio)
Applications of immunohistochemistry techniques to culture of juxtaglomerular cells.
1989 Tsukuba University (Japan, Professor K. Murakami)
Regulation of renin gene in chorionic cells using CAT reporter gene.
1991 Zurich University (Switzerland, Professor A. Kurtz)
Intracellular calcium measurement in a single chorionic cell using fura-2.
1999 Visiting researcher at Harvard University (USA, MGH, Boston, Professor M. C. Fishman) Morphological characterization of zebra fish presenting cardiac abnormalities.
2001-2010 Board member of SFHTA (French Society of Arterial Hypertension)
2004-2009 Board member of cardiovascular scientific committee of « Fondation de France ».
2005-2009 Board member of European Council for Cardiovascular Research
2008-2013 Board member of SFC (French Society of Cardiology)
2003 Prize of cardiovascular research JP Binet (FRM)
2006 Labellisation of the research team by FRM
After PhD studies in Paris (France) on regulation of human renin gene expression using different cell lines producing renin and transgenic mice, I developped transcriptional studies on endothelin system.
I moved in 2000 to Lille (France) and as leader of an Inserm team, I developed a translational research with the aim to find new biomarkers in cardiovascular diseases, mainly left ventricular remodeling post-myocardial infarction and abdominal aortic aneurysm, using differential proteomic analysis.
For that purpose, we were the first to establish the reference 2D maps of human macrophages and smooth muscle cells. We have developed proteomic techniques dedicated to human biological samples (plasma, serum, vascular cells): 2D-DIGE electrophoresis using saturating Cyanine-dyes, SELDI-TOF analysis. We have developed techniques allowing the analysis of “deep plasma” proteome and phosphorylation and O-N-acetyl-glucosaminylation. We have also the expertise of techniques allowing the verification and validation of the proteins selected from the proteomic analysis (western blot, immnuofluorescence and immunohistochemistry, ELISA).
We developed clinical studies recruiting patients precisely phenotyped for the cardiovascular diseases studied with biological samples collected for proteomic analysis. For abdominal aortic aneurysm and left ventricular remodeling post-infarction, we found several proteins modulated in diseased patients by differential proteomic analysis of vascular cells or plasma. More recently, using phosphoproteomic and an experimental model of myocardial infarction in animals, we found a decrease of phosphorylated troponin T in left ventricle of heart failure animals. We developed tools (specific antibodies) to detect the phosphorylated form of troponin T in plasma of the same animals. Then, we validated in patients with high left ventricular remodeling post-infarction, the decrease of phosphorylation of troponin T, suggesting that the level of phosphorylation of troponin T could be a new biomarker and help to predict this effect in high risk patients.
Patent: WO 2010/133655 A1 (25 November 2010) Pinet F, Mulder P, Bauters C, Richard V.Post-translation modified cardiac troponin T as a biomarker of a risk for heart failure.